Efficacy of Atezolizumab + Bevacizumab in Advanced HCC

One of the most common causes of cancer-related death worldwide is hepatocellular carcinoma (HCC). Atezolizumab combined with Bevacizumab ( Atezolizumab + Bevacizumab) has been the standard of care (SoC) in 1st-line (L1) advanced and metastatic hepatocellular carcinoma (HCC) since January 2020.

The data from the IMbrave 150 trial, showed an enhanced overall survival (OS) and low toxicity vs Nexavar. There are currently few real-life data on the use of this combination.

Fabien Moinard-Butot and the team evaluated the efficacy and tolerability of Atezolizumab + Bevacizumab in patients (pts) with locally advanced and metastatic HCC.

Researchers conducted a retrospective study of patient samples obtained from pts from 6 varied French centers. These samples included samples from pts with treated with Atezolizumab + Bevacizumab for locally advanced and metastatic HCC. The evaluation of OS, progression free survival (PFS), and tolerability were the key parameters of the analysis and were grouped based on the cirrhosis levels.

Data revealed that between February 2020 and October 2022, 70 pts with metastatic HCC were enrolled in the study. The median age was 70 years, and almost 94% pts were men. Most pts had a WHO status of <2 (89%). Cirrhosis was present in 55 pts (79%), with 75% having non-viral, 15% viral, and 10% mixed causes. CHILD A cirrhosis was prevailing, affecting 85% of the pts. Before treatment, 18 pts (33%) had esophageal varices.

The median OS was 19 months (95% CI, 15-NE), and the median PFS was 6.8 months (95% CI, 4.7-14.2). Patients with CHILD A cirrhosis demonstrated significantly better median OS vs those with CHILD B cirrhosis (P = 0.03). The treatment-related toxicity led to treatment termination 5 pts. Patients received a second-line (2L) treatment at a 37% disease progression rate (DPR).

These findings pinpoint the population characteristics, survival outcomes, and treatment patterns observed in pts with metastatic HCC treated with Atezolizumab + Bevacizumab in a real-world analysis across various French centers.

The study concluded that Atezolizumab + Bevacizumab found effective and well tolerated. About less than 50% pts were able to receive 2L treatment after progression.

The study received no funding.

Source: https://cslide.cReviewedtimeetingtech.com/esmogi24hybrid/attendee/confcal/show/session/3

Butot F.M., Richaud J.B.B., Wetzel S.H., et al. (2024). “Retrospective multicenter real-life study evaluating the efficacy of atezolizumab in combination with bevacizumab in metastatic hepatocellular carcinoma: HIREAL study.” Presented at ESMO-GI 2024, (Abstract 201P).